Home Newsfeeds BioCryst Pharmaceuticals Granted Orphan Drug Designation For The Treatment Of Fibrodysplasia Ossificans Progressiva

BioCryst Pharmaceuticals Granted Orphan Drug Designation For The Treatment Of Fibrodysplasia Ossificans Progressiva

https://www.scribd.com/document/589941834/BCRX-Orphan-Drug

byBenzinga Newsdesk

August 29, 2022

1 minute read

Ford, SK On, EcoProBM Invest ~$888M To Build Cathode Manufacturing Facility In Canada

By Nabaparna Bhattacharya

August 17, 1:06 PM

Ford Motor Company (NYSE: F) formed a consortium with SK On Co Ltd and EcoProBM to invest C$1.2 billion (~$887.51 million) in building a cathode manufacturing facility in Becancour, Quebec.

Movers
News

What’s Going On With Tesla Stock?

By Erica Kollmann

August 2, 12:55 PM

Tesla, Inc. (NASDAQ: TSLA) shares are trading lower on Wednesday. The stock

TSLA

Softer Demand For Chemicals Hurts Leslie’s Amid Macro Woes, Analyst Lowers Price Target

By Nabaparna Bhattacharya

July 14, 12:56 PM

Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on Leslie's, Inc. (NASDAQ: LESL),

LESL

UBS Downgrades Mondelez International to Neutral, Raises Price Target to $71

By Benzinga Newsdesk

December 8, 7:12 AM

UBS analyst Cody Ross downgrades Mondelez International (NASDAQ:MDLZ) from Buy to Neutral and raises the price target from $70 to $71.

MDLZ

BioCryst Pharmaceuticals Granted Orphan Drug Designation For The Treatment Of Fibrodysplasia Ossificans Progressiva

Related Posts

Ford, SK On, EcoProBM Invest ~$888M To Build Cathode Manufacturing Facility In Canada

What’s Going On With Tesla Stock?

Softer Demand For Chemicals Hurts Leslie’s Amid Macro Woes, Analyst Lowers Price Target

UBS Downgrades Mondelez International to Neutral, Raises Price Target to $71